| UK’s first double high-dose cancer treatment delivered in Bristol
Patients are normally suffering from locally-advanced prostate cancer and receive brachytherapy as a boost prior to receiving a full course of external beam radiotherapy. Bristol Oncology Centre, which serves 2.4 million people in the Avon, Somerset and Wiltshire region, has been using a Varian GammaMed afterloader since 2005. The device is used in combination with BrachyVision treatment planning software, which enables clinicians to plan treatments by combining and using MRI, CT and 3D scans for the best possible images of the tumor and surrounding organs. .
Indevus Pharmaceuticals Announces PRO 2000 Found to Show Promise
The Company's approved products include SANCTURA(R) and SANCTURA XR(TM) for overactive bladder, VANTAS(R) for advanced prostate cancer, SUPPRELIN(R) LA for central precocious puberty, and DELATESTRYL(R) to treat male hypogonadism. The Indevus development pipeline contains multiple compounds within the Company's core therapeutic areas in addition to several partnered or partnerable programs. The most advanced compounds in development include, VALSTAR(TM) for bladder cancer, NEBIDO(R) for hypogonadism, PRO 2000 for the prevention of infection by HIV and other sexually-transmitted pathogens, the octreotide implant for acromegaly and carcinoid syndrome, and pagoclone for stuttering. PRO 2000 PRO 2000 (a naphthalene sulfonate polymer) is under development as a topical vaginal microbicide to prevent the sexual transmission of HIV and other sexually transmitted diseases.
Nektar Therapeutics Starts Dosing in Phase 1 Study of NKTR-105 in
The compound is currently approved for breast, non-small cell lung, prostate, gastric and head and neck cancers.
The company noted that the compound has a prolonged half life and tumor exposure compared to docetaxel. Nektar expects that its advanced polymer conjugate technology can be used to optimize the bioactivity of the drugs and increase the sustained exposure of active drug to tumor cells in the body. .
Dyserth youngster battling back after neuroblastoma fight
The parents of a girl battling a rare form of cancer have told of their turmoil. Brave Natasha Davies is nearing her 10th birthday – her smile hides her torturous journey of gruelling chemotherapy and operations. The Ysgol Penmorfa pupil from Dyserth, who plays the flute and loves art, has been battling neuroblastoma since she was just 18 moths old. Devoted parents Deryck and Wanda remember only too well the painful memories of discovering a tumour growing in their daughter's chest when. "We became concerned when Natasha turned very pale and lost a lot of weight," said Deryck. Their worst fears were confirmed soon after tests and Natasha was admitted to Liverpool's Alder Hey Children's Hospital. Treatment was tough on Natasha, and when chemotherapy did not shrink the size of the tumour sufficiently, she had two ribs removed.
Early detection key to surviving prostate cancer
Portee's brother, Wayne, is also a prostate cancer survivor. "Ramon had it first. Then I started having trouble. I didn't think it would happen to me. It did."I had surgery in April 2001. In 2003, I had 39 radiation treatments. Tell every guy you know to take a test."Take the Portees' advice and take the opportunity for free prostate screening, being offered from noon to 3 p.m. Saturday in Elks Lakeview Lodge 1132, 1080 S. Franklin St. It's sponsored by the Emanon Club and the Macon County Health Department.It's the first time the Lakeview Elks Lodge has entered the prostate screening campaign, John Wilder said. He is the club's assistant social chairman and is a three-year prostate cancer survivor.Another survivor, Jerry Smalling, a retired high school coach, said he had radical prostate surgery in 1998.
High Interest
This study to determine whether or not Selenium and Vitamin E can be effective in the prevention of prostate cancer has been ongoing for more than five years. Mazzarella was chosen to be a member of this advisory board in 2003. Mazzarella is participating in the trial through Pardee Hospital�s Comprehensive Cancer Center. .
Major study on DiagnoCure's GCC biomarker published in Jama
The Company also has a strategic alliance with Gen-Probe (NASDAQ: GPRO) for the development and commercialization of a second-generation prostate cancer test using PCA3, DiagnoCure's proprietary molecular marker. This test is also available through laboratories in the U.S. using PCA3 analyte specific reagents (ASR) from Gen-Probe, in Europe as the CE-marked PROGENSA(TM) PCA3 in vitro assay, and in Canada. For more information, visit www.diagnocure.com. Forward-looking statements This release contains forward-looking statements that involve known and unknown risks, uncertainties and assumptions that may cause actual results to differ materially from those expected. By their very nature, forward-looking statements are based on expectations and hypotheses and also involve risks and uncertainties, known and unknown, many of which are beyond DiagnoCure's control.
Dr. Victor Forys, Press Conference
We need to stop dividing patients into women, men, breast cancer patients, prostate cancer patients, asthma patients, hypertension patients, diabetes patients, and unite ALL PATIENTS to pass real health insurance coverage for people over age 49 that get any illness or cancer, even if they lose their job. That is the real issue" said Dr. Victor Forys. "We are all patients," said Dr. Victor Forys. "The biggest threat to the health of millions of Americans isn't cancer, diabetes, heart disease, or high blood pressure, it's the lack of health care coverage and we can cure that right now," Dr. Victor Forys "That's the biggest threat to the health of Americans - one in six, 47 million Americans lack insurance," said Dr. Forys. Contrary to Sara's new slick television ad, the battle is not over.
At last we're talking about the Big C: Cancer specialist says we
Within 20 years cancer will be considered a chronic disease, joining conditions such as diabetes, heart disease and asthma. The model of prostate cancer, where many die with it rather than from it, will be common. When cancer does develop, refinements of current technologies and techniques – in imaging, radiotherapy and surgery – together with the availability of targeted drugs
will make it controllable. Cure will not be the only satisfactory outcome. Fear that cancer will definitely kill will be replaced by an acceptance that many forms of cancer are a consequence of age. Well-informed patients, with adequate funds, will ensure that they have rapid access to the newest and the best, wherever it is in the world. More patients will benefit from better diagnosis and treatments, with greater emphasis on quality of life.
Many men would consider breast reduction
They can be the side-effect of legal drugs (such as those used in prostate cancer) and illegal drugs (steroids). Or the cause can be genetic. In boys and younger men, enlarged breast tissue can result from a temporary hormonal imbalances triggered at puberty. Some experts have theorised that hormone-imitating substances found in plastics and elsewhere in our increasingly unnatural environment might be causing similar hormonal imbalances in older men leading to moobs. More snap survey results Your Comments (no links please)
.
|
